SCHEMBL25510504

SCHEMBL25510504

Cc1ccc(C(C)C)c(OCC(F)(F)F)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 3/20 0.36
CYP17A1 P05093 2/20 0.36
CYP2C9 P11712 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
CYP1A2 P05177 1/20 0.36
CNR2 P34972 4/20 0.35
MDM2 Q00987 1/20 0.35
RXRA P19793 1/20 0.34
NPC1 O15118 1/20 0.33
RECQL P46063 1/20 0.33
RAB9A P51151 1/20 0.33
AAK1 Q2M2I8 1/20 0.32
PTGS2 P35354 2/20 0.32
PTGS1 P23219 1/20 0.32
LMNA P02545 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
HCRTR1 O43613 1/20 0.32
HCRTR2 O43614 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23977890 0.80 CNR2 (0.50) CYP2C19CYP17A1CYP2C9MEN1KMT2A
SCHEMBL25163559 0.78 P2RY1 (0.34) CYP1A2MDM2NPC1RECQLRAB9A
SCHEMBL21756757 0.77 ALDH1A1 (0.42) MEN1KMT2ACNR2PTGS2PTGS1
SCHEMBL23082903 0.75 SCN9A (0.41) CYP2C19CYP17A1CYP2C9HCRTR1HCRTR2
SCHEMBL8234881 0.74 TSHR (0.37) CYP2C19CYP2C9MEN1KMT2ACYP1A2
SCHEMBL8737283 0.73 LPAR1 (0.40) NPC1RAB9ALMNALPAR1
SCHEMBL20057276 0.72 SSTR4 (0.52) CNR2
SCHEMBL15350504 0.72 L3MBTL1 (0.43) MEN1KMT2ACNR2RXRAPTGS1
SCHEMBL12871319 0.72 NOTUM (0.34) CYP2C19RAB9ALMNA
SCHEMBL18371947 0.71 PTGS2 (0.36) CYP2C19CYP17A1CYP2C9MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230147428-A1 BENZIMIDAZOLONE-BASED CINNAMAMIDE DERIVATIVE AS TRPV1 ANTAGONIST AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF PAIN CONTAINING SAME AS ACTIVE INGREDIENT JMACKEM CO., LTD (KR) 2023-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230147428-A1 BENZIMIDAZOLONE-BASED CINNAMAMIDE DERIVATIVE AS TRPV1 ANTAGONIST AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF PAIN CONTAINING SAME AS ACTIVE INGREDIENT TRPV1, TRPA1, TRPV5 CYP2C19 549/4885CYP17A1 2596/4885CYP2C9 1280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.